A client is newly diagnosed with benign prostatic hyperplasia (BPH). Which of the following medications are NOT used to treat BPH? (Select All That Apply.)

Choice A rationale

Spironolactone is a potassium-sparing diuretic that acts on the collecting ducts and late distal tubules but not on the loop of Henle.

Choice B rationale

Hydrochlorothiazide is a thiazide diuretic that works on the distal convoluted tubule, not the loop of Henle.

Choice C rationale

Furosemide is a loop diuretic that acts on the ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption, leading to increased urine output.

Choice D rationale

Mannitol is an osmotic diuretic that primarily acts on the proximal tubule and the descending limb of the loop of Henle.

Choice A rationale

A receptor antagonist blocks the effects of normal cellular functions by binding to receptor sites and preventing endogenous substances (like hormones or neurotransmitters) from activating those receptors.

Choice B rationale

Receptor antagonists do not accelerate hormones attaching to cell receptor sites; they prevent this process by blocking the receptors.

Choice C rationale

Receptor antagonists do not minimize the risk of other medications becoming toxic. They specifically block the action of certain endogenous substances.

Choice D rationale

Receptor antagonists do not increase the action of cells; rather, they inhibit or block the usual effects.